FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022971808> ?p ?o ?g. }

• W2022971808 endingPage "268.e1" @default.
• W2022971808 startingPage "263" @default.
• W2022971808 abstract "Objective To review longitudinal polysomnography data to assess sleep-related disordered breathing (SRDB) before and up to 2 years after initiation of growth hormone (GH) therapy in children with Prader-Willi syndrome (PWS). Study design This was a retrospective review of systematic polysomnography evaluations performed in children with PWS before and at 6 weeks, 6 months, 1 year, and 2 years after initiation of GH therapy. Results A total of 15 children with PWS were reviewed. At baseline, the median age was 3.7 years (range, 0.8-15.4 years), and the median body mass index percentile was 82.4 (range, 0-100). GH was discontinued in 2 of these 15 children owing to the occurrence of severe obstructive sleep apnea after 6 weeks of GH therapy. The remaining 13 children who were followed for up to 2 years on GH therapy demonstrated no statistically significant trends over time for any adverse sleep-related outcomes, specifically obstructive or central sleep apnea. Conclusion In young children with PWS with known SRDB at baseline, the first few weeks after initiation of GH therapy may represent a vulnerable time for the development of significant SRDB. However, most children with PWS did not show significant changes in SRDB after 2 years of GH therapy. We conclude that long-term GH therapy appears to be safe after an initial period of increased risk in the context of SRDB in children with PWS. To review longitudinal polysomnography data to assess sleep-related disordered breathing (SRDB) before and up to 2 years after initiation of growth hormone (GH) therapy in children with Prader-Willi syndrome (PWS). This was a retrospective review of systematic polysomnography evaluations performed in children with PWS before and at 6 weeks, 6 months, 1 year, and 2 years after initiation of GH therapy. A total of 15 children with PWS were reviewed. At baseline, the median age was 3.7 years (range, 0.8-15.4 years), and the median body mass index percentile was 82.4 (range, 0-100). GH was discontinued in 2 of these 15 children owing to the occurrence of severe obstructive sleep apnea after 6 weeks of GH therapy. The remaining 13 children who were followed for up to 2 years on GH therapy demonstrated no statistically significant trends over time for any adverse sleep-related outcomes, specifically obstructive or central sleep apnea. In young children with PWS with known SRDB at baseline, the first few weeks after initiation of GH therapy may represent a vulnerable time for the development of significant SRDB. However, most children with PWS did not show significant changes in SRDB after 2 years of GH therapy. We conclude that long-term GH therapy appears to be safe after an initial period of increased risk in the context of SRDB in children with PWS." @default.
• W2022971808 created "2016-06-24" @default.
• W2022971808 creator A5015746267 @default.
• W2022971808 creator A5017484889 @default.
• W2022971808 creator A5043495018 @default.
• W2022971808 creator A5059867188 @default.
• W2022971808 creator A5086418012 @default.
• W2022971808 creator A5087534133 @default.
• W2022971808 date "2013-02-01" @default.
• W2022971808 modified "2023-09-27" @default.
• W2022971808 title "Longitudinal Evaluation of Sleep-Disordered Breathing in Children with Prader-Willi Syndrome during 2 Years of Growth Hormone Therapy" @default.
• W2022971808 cites W1972361219 @default.
• W2022971808 cites W1981772597 @default.
• W2022971808 cites W2003297134 @default.
• W2022971808 cites W2005014423 @default.
• W2022971808 cites W2007696685 @default.
• W2022971808 cites W2018469561 @default.
• W2022971808 cites W2023016754 @default.
• W2022971808 cites W2039055915 @default.
• W2022971808 cites W2060234459 @default.
• W2022971808 cites W2062934156 @default.
• W2022971808 cites W2074245011 @default.
• W2022971808 cites W2074596047 @default.
• W2022971808 cites W2076734066 @default.
• W2022971808 cites W2080876236 @default.
• W2022971808 cites W2101872157 @default.
• W2022971808 cites W2115123766 @default.
• W2022971808 cites W2145730830 @default.
• W2022971808 cites W2146605832 @default.
• W2022971808 cites W2158456175 @default.
• W2022971808 cites W2169124971 @default.
• W2022971808 cites W2264637802 @default.
• W2022971808 cites W2272275419 @default.
• W2022971808 cites W4251031798 @default.
• W2022971808 cites W4297900733 @default.
• W2022971808 doi "https://doi.org/10.1016/j.jpeds.2012.07.042" @default.
• W2022971808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22947651" @default.
• W2022971808 hasPublicationYear "2013" @default.
• W2022971808 type Work @default.
• W2022971808 sameAs 2022971808 @default.
• W2022971808 citedByCount "49" @default.
• W2022971808 countsByYear W20229718082013 @default.
• W2022971808 countsByYear W20229718082014 @default.
• W2022971808 countsByYear W20229718082015 @default.
• W2022971808 countsByYear W20229718082016 @default.
• W2022971808 countsByYear W20229718082017 @default.
• W2022971808 countsByYear W20229718082018 @default.
• W2022971808 countsByYear W20229718082019 @default.
• W2022971808 countsByYear W20229718082020 @default.
• W2022971808 countsByYear W20229718082021 @default.
• W2022971808 countsByYear W20229718082022 @default.
• W2022971808 countsByYear W20229718082023 @default.
• W2022971808 crossrefType "journal-article" @default.
• W2022971808 hasAuthorship W2022971808A5015746267 @default.
• W2022971808 hasAuthorship W2022971808A5017484889 @default.
• W2022971808 hasAuthorship W2022971808A5043495018 @default.
• W2022971808 hasAuthorship W2022971808A5059867188 @default.
• W2022971808 hasAuthorship W2022971808A5086418012 @default.
• W2022971808 hasAuthorship W2022971808A5087534133 @default.
• W2022971808 hasConcept C126322002 @default.
• W2022971808 hasConcept C151730666 @default.
• W2022971808 hasConcept C187212893 @default.
• W2022971808 hasConcept C2776006263 @default.
• W2022971808 hasConcept C2777935920 @default.
• W2022971808 hasConcept C2778205975 @default.
• W2022971808 hasConcept C2779343474 @default.
• W2022971808 hasConcept C2780221984 @default.
• W2022971808 hasConcept C2781326671 @default.
• W2022971808 hasConcept C2984496839 @default.
• W2022971808 hasConcept C3018790630 @default.
• W2022971808 hasConcept C71315377 @default.
• W2022971808 hasConcept C71924100 @default.
• W2022971808 hasConcept C86803240 @default.
• W2022971808 hasConceptScore W2022971808C126322002 @default.
• W2022971808 hasConceptScore W2022971808C151730666 @default.
• W2022971808 hasConceptScore W2022971808C187212893 @default.
• W2022971808 hasConceptScore W2022971808C2776006263 @default.
• W2022971808 hasConceptScore W2022971808C2777935920 @default.
• W2022971808 hasConceptScore W2022971808C2778205975 @default.
• W2022971808 hasConceptScore W2022971808C2779343474 @default.
• W2022971808 hasConceptScore W2022971808C2780221984 @default.
• W2022971808 hasConceptScore W2022971808C2781326671 @default.
• W2022971808 hasConceptScore W2022971808C2984496839 @default.
• W2022971808 hasConceptScore W2022971808C3018790630 @default.
• W2022971808 hasConceptScore W2022971808C71315377 @default.
• W2022971808 hasConceptScore W2022971808C71924100 @default.
• W2022971808 hasConceptScore W2022971808C86803240 @default.
• W2022971808 hasIssue "2" @default.
• W2022971808 hasLocation W20229718081 @default.
• W2022971808 hasLocation W20229718082 @default.
• W2022971808 hasOpenAccess W2022971808 @default.
• W2022971808 hasPrimaryLocation W20229718081 @default.
• W2022971808 hasRelatedWork W1971395675 @default.
• W2022971808 hasRelatedWork W1989964341 @default.
• W2022971808 hasRelatedWork W2046839106 @default.
• W2022971808 hasRelatedWork W2069748390 @default.
• W2022971808 hasRelatedWork W2416538410 @default.
• W2022971808 hasRelatedWork W2888977557 @default.

• next